metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mGC or mGEJC - L1 - HER2 neg/PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 neg/PDL1 positive
versus Standard of Care (SoC)
	nivolumab plus SoC
	CheckMate 649 (PDL1 CPS>5), 2021 Lancet 2021 Jun 4;S0140-6736(21)00797-2. NCT02872116	RCT	mGC or mGEJC - L1 - HER2 neg/PDL1 positive	nivolumab plus chemotherapy	ICC (XELOX, FOLFOX)	previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma, only patients with PDL1 CPS>5	473 / 482	some concern	conclusif	demonstrated 29 % decrease in deaths (OS) (PE) demonstrated 32 % decrease in progression or deaths (PFS) (PE)
	CheckMate 649 (PDL1 CPS>1), 2021 Lancet 2021 Jun 4;S0140-6736(21)00797-2. NCT02872116	RCT	mGC or mGEJC - L1 - HER2 neg/PDL1 positive	nivolumab plus chemotherapy	ICC (XELOX, FOLFOX)	previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma, only patients with PDL1 CPS>1	641 / 655	some concern	conclusif	demonstrated 23 % decrease in deaths (OS) (PE) suggested 26 % decrease in progression or deaths (PFS)
mGC or mGEJC - L1 - HER2 negative metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - HER2 negative
versus Standard of Care (SoC)
	nivolumab plus SoC
	CheckMate 649, 2021 Lancet 2021 Jun 4;S0140-6736(21)00797-2. Nature 2022 Mar;603(7903):942-948. NCT02872116	RCT	mGC or mGEJC - L1 - HER2 negative	nivolumab plus chemotherapy	ICC (XELOX, FOLFOX)	previously untreated, non-HER2-positive, advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma	789 / 792	some concern	conclusif	demonstrated 20 % decrease in deaths (OS) (PE) suggested 23 % decrease in progression or deaths (PFS)
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus placebo
	nivolumab alone
	ATTRACTION-2 (Kang), 2017 Gastric Cancer 2019; 22:344-354 Gastric Cancer 2020; 23:143-153 Gastric Cancer 2021 Mar 20. Lancet 2017; 390:2461-2471 NCT02267343	RCT	mGC or mGEJC - L2 - all population	nivolumab	placebo	patients with advanced gastric or gastro-oesophageal junction cancer who had been previously been treated with two or more chemotherapy regimens	330 / 163	low	inconclusive	suggested 37 % decrease in deaths (OS) (PE) suggested 38 % decrease in deaths (OS) (extension) suggested 40 % decrease in PFS (extension) suggested 40 % decrease in progression or deaths (PFS)